ReviewSeminars in oncology2014
Estrongenic steroid hormones in lung cancer.
Review in Seminars in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Pooled it
- Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2018Trial
- Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial.Clinical lung cancer · 2016Trial
- Review
- Sex, hormones, and lung health.Physiological reviews · 2026Review
- Beyond tobacco: understanding the growing burden of lung adenocarcinoma in women.Oncology reviews · 2026Review
- Prognostic influence of chronic inflammation in patients with head and neck cancer based on sex differences.Clinical & experimental metastasis · 2025Review
- Decoding the mechanisms behind second primary cancers.Journal of translational medicine · 2025Review
- Case Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib.Frontiers in oncology · 2025Article
- Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile.Frontiers in immunology · 2025Article
- Review
- Reproductive factors and risk of lung cancer among 300,000 Chinese female never-smokers: evidence from the China Kadoorie Biobank study.BMC cancer · 2024Article
- Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity.BMC cancer · 2023Article
- Intratumoral Microbiota-Host Interactions Shape the Variability of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma in Recurrence and Metastasis.Microbiology spectrum · 2023Article
- Pregnancy may have little influence on ground-glass opacities suspected for lung adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- ER predicts poor prognosis in male lung squamous cell cancer of stage IIIA-N2 disease after sequential adjuvant chemoradiotherapy.Frontiers in oncology · 2023Article
- Sex-specificity in Surgical Stages of Lung Cancer in Young Adults.The open respiratory medicine journal · 2023Article
- Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.The Lancet regional health. Europe · 2022Article
- Estrogens, Cancer and Immunity.Cancers · 2022Review
- High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It is becoming increasingly clear that steroid hormones are involved in the biology of many organs outside the reproductive system. Evidence has been accumulating since the mid 1990s that the lung contains receptors for both estrogen and progesterone and that these hormones have some role in lung development, pulmonary inflammation, and lung cancer. The estrogen receptor β (ERβ) is the major ER expressed in lung tissues, while inflammatory cells capable of infiltrating the lung are reported to express both ERα and ERβ. Although there is evidence in animals of preferential effects of ERβ in the lungs of females, human lung tumors from males also contain ERβ-positive cells and express aromatase, the enzyme that converts testosterone to estrogens. This review will discuss current literature findings on the role of the ERs and the progesterone receptor (PR), as well CYP19 (aromatase), the rate-limiting enzyme in the synthesis of estrogen, in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.